Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: tolvaptan

« Back to Dashboard

Summary for Generic Name: tolvaptan

Tradenames:1
Patents:3
Applicants:1
NDAs:1
Drug Master File Entries: see list6
Suppliers: see list1

Clinical Trials for: tolvaptan

Effects of Tolvaptan in Healthy Adults
Status: Recruiting Condition: Healthy

A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Status: Recruiting Condition: Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)
Status: Active, not recruiting Condition: Nephropathy

Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
Status: Completed Condition: Ascites; Hepatic Cirrhosis

Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Status: Terminated Condition: Hyponatremia; Dilutional Hyponatremia; Inappropriate ADH Syndrome

Tolvaptan for Ascites in Cirrhotic Patients
Status: Active, not recruiting Condition: Ascites; Cirrhosis

Tolvaptan in Hyponatremic Cancer Patients
Status: Completed Condition: Advanced Cancers

Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact
Status: Completed Condition: Healthy

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Completed Condition: Autosomal Dominant Polycystic Kidney Disease

Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites
Status: Recruiting Condition: Cirrhosis; Refractory/Recurrent Ascites

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275May 19, 2009DISCNNo5,258,510<disabled>YY<disabled>
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275May 19, 2009DISCNNo8,501,730<disabled>Y<disabled>
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275May 19, 2009RXNo5,258,510<disabled>YY<disabled>
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275May 19, 2009RXYes<disabled><disabled>
Otsuka America Pharm
SAMSCA
tolvaptan
TABLET;ORAL022275May 19, 2009DISCNNo5,753,677<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc